Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021
November 03 2021 - 8:00AM
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage
company developing precision oncology therapeutics, today announced
it will report financial results for the third quarter that ended
September 30, 2021 and highlights of recent progress, on Wednesday,
November 10, 2021. On that day, management will host a conference
call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the
Company’s business and financial results.
Conference Call and Webcast Details:Date:
November 10, 2021Time: 1:30 p.m. PT (4:30 p.m. ET)Dial In Numbers:
1 (833) 562-0127 (U.S. Toll Free) / 1 (661) 567-1105 (U.S.
Toll)Passcode: 1985710 Webcast Link:
https://edge.media-server.com/mmc/p/6qek8226
The call will be recorded and available for replay on the
Company’s website for approximately 30 days after the call.
About Rain Therapeutics Inc.Rain Therapeutics
Inc. is a late-stage precision oncology company developing
therapies that target oncogenic drivers for which it is able to
genetically select patients it believes will most likely benefit.
This approach includes using a tumor-agnostic strategy to select
patients based on their tumors’ underlying genetics rather than
histology. Rain’s lead product candidate, milademetan (RAIN-32), is
a small molecule, oral inhibitor of MDM2, which is oncogenic in
numerous cancers. In addition to milademetan, Rain is also
developing a preclinical program that is focused on inducing
synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact:Jordyn TemperatoLifeSci
Communications +1.646.876.5196 jtemperato@lifescicomms.com
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Apr 2023 to Apr 2024